1984
BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
Bakemeier R, Anderson J, Costello W, Rosner G, Horton J, Glick J, Hines J, Berard C, DeVita V. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study. Annals Of Internal Medicine 1984, 101: 447-56. PMID: 6089632, DOI: 10.7326/0003-4819-101-4-447.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBlood Cell CountCarmustineClinical Trials as TopicCombined Modality TherapyCyclophosphamideFemaleGastrointestinal DiseasesHematologic DiseasesHodgkin DiseaseHumansMaleMechlorethamineNeoplasm StagingPeripheral Nervous System DiseasesPrednisoneProcarbazineRandom AllocationVinblastineVincristineConceptsAdvanced Hodgkin's diseaseHodgkin's diseaseUntreated patientsEastern Cooperative Oncology Group studyDuration of complete remissionRandomized prospective studyTreatment of patientsMOPP regimenHematologic toxicityInduction chemotherapyComplete remissionChemotherapy regimensRemission rateNeurological toxicityProspective studyMOPPRemissionTherapeutic benefitChemotherapyPatientsInduction phaseDiseaseToxicityGroup studyDuration
1980
Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease.
Fisher R, DeVita V, Bostick F, Vanhaelen C, Howser D, Hubbard S, Young R. Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease. Annals Of Internal Medicine 1980, 92: 595-9. PMID: 6992672, DOI: 10.7326/0003-4819-92-5-595.Peer-Reviewed Original ResearchConceptsLong-term survivorsMitogen-induced lymphocyte proliferationPersistent immunologic abnormalitiesHodgkin's diseaseImmunologic abnormalitiesE rosettesLymphocyte proliferationAdvanced diffuse histiocytic lymphomaDepressed cellular immunityAdvanced Hodgkin's diseaseDisease-free intervalDiffuse histiocytic lymphomaB cell numbersNormal control subjectsComparable chemotherapyMOPP chemotherapyUntreated patientsCellular immunityControl subjectsHistiocytic lymphomaImmunologic studiesNormal rangeControl populationChemotherapyAbnormalities
1979
Chemotherapy of Hodgkin's disease
Young R, DeVita V. Chemotherapy of Hodgkin's disease. Clinics In Haematology 1979, 8: 625-644. PMID: 91466, DOI: 10.1016/s0308-2261(79)80007-7.Peer-Reviewed Original ResearchConceptsAdvanced diseaseHodgkin's diseaseModality approachSuch long-term complicationsIIIB Hodgkin's diseaseInduction chemotherapy regimensPrimary induction failureShort initial remissionAdvanced Hodgkin's diseaseDisease-free survivalOverall survival ratePrognosis of patientsLong-term complicationsInduction failureAggressive therapyChemotherapy regimensComplete remissionInitial remissionLate complicationsSecond malignanciesCombination chemotherapySurvival benefitMOPP regimenActual survivalCombined modality
1978
The chemotherapy of Hodgkin's disease. Past experiences and future directions
Devita V, Lewis B, Rozencweig M, Muggia F. The chemotherapy of Hodgkin's disease. Past experiences and future directions. Cancer 1978, 42: 979-990. PMID: 356960, DOI: 10.1002/1097-0142(197808)42:2+<979::aid-cncr2820420721>3.0.co;2-s.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseCombination chemotherapyAntitumor response rateAdvanced Hodgkin's diseaseComplete remissionDrug therapyDrug combinationsEffective treatmentTherapeutic experimentsAntitumor effectsResponse rateChemotherapyClinical investigatorsNatural historyEffective agentDiseasePatientsMarked increaseTreatmentNitrogen mustardRemissionTherapyPatterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy
Young R, Canellos G, Chabner B, Hubbard S, Devita V. Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. Cancer 1978, 42: 1001-1007. PMID: 688174, DOI: 10.1002/1097-0142(197808)42:2+<1001::aid-cncr2820420723>3.0.co;2-z.Peer-Reviewed Original ResearchConceptsPatterns of relapseAdvanced Hodgkin's diseaseComplete remissionCombination chemotherapyHodgkin's diseasePrevious diseaseNodal sitesNodular sclerosis histologyProphylactic radiation therapyLeft supraclavicular areaSite of diseaseNodal diseaseSystemic symptomsSupraclavicular areaRadiation therapyRelapse increasesNodal areasPatientsRelapseDiseaseRemissionChemotherapyHistologyTherapy
1975
In vitro granulocyte production in patients with Hodgkin's disease and lymphocytic, histiocytic, and mixed lymphomas.
Bull J, DeVita V, Carbone P. In vitro granulocyte production in patients with Hodgkin's disease and lymphocytic, histiocytic, and mixed lymphomas. Blood 1975, 45: 833-42. PMID: 1125431, DOI: 10.1182/blood.v45.6.833.bloodjournal456833.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseMixed lymphomaUntreated patientsHistiocytic-lymphocytic lymphomasAdvanced Hodgkin's diseaseMOPP chemotherapyGranulocyte colony formationCombination chemotherapyMarrow culturesCFU-CIn vitro examinationLymphomaChemotherapyGranulocyte productionPatientsLong-term effectsAcute responseHodgkinColony formationDecreased numberDiseaseColony growthIn Vitro Granulocyte Production in Patients With Hodgkin’s Disease and Lymphocytic, Histiocytic, and Mixed Lymphomas
Bull J, DeVita V, Carbone P. In Vitro Granulocyte Production in Patients With Hodgkin’s Disease and Lymphocytic, Histiocytic, and Mixed Lymphomas. Blood 1975, 45: 833-842. DOI: 10.1182/blood.v45.6.833.833.Peer-Reviewed Original ResearchHodgkin's diseaseMixed lymphomaUntreated patientsHistiocytic-lymphocytic lymphomasAdvanced Hodgkin's diseaseMOPP chemotherapyGranulocyte colony formationCombination chemotherapyMarrow culturesCFU-CIn vitro examinationLymphomaChemotherapyGranulocyte productionPatientsLong-term effectsAcute responseHodgkinColony formationDecreased numberDiseaseColony growth
1973
Combination Chemotherapy and Survival in Advanced Hodgkin's Disease
Canellos G, Young R, Berard C, DeVita V. Combination Chemotherapy and Survival in Advanced Hodgkin's Disease. JAMA Internal Medicine 1973, 131: 388-390. PMID: 4569375, DOI: 10.1001/archinte.1973.00320090078008.Peer-Reviewed Original Research
1972
A decade of combination chemotherapy of advanced Hodgkin's disease
Devita V, Canellos G, Moxley J. A decade of combination chemotherapy of advanced Hodgkin's disease. Cancer 1972, 30: 1495-1504. PMID: 4565815, DOI: 10.1002/1097-0142(197212)30:6<1495::aid-cncr2820300613>3.0.co;2-i.Peer-Reviewed Original ResearchConceptsAdvanced Hodgkin's diseaseComplete remission rateHodgkin's diseaseRemission rateRemission durationCombination chemotherapySingle agentLonger disease-free intervalDisease-free intervalAcute childhood leukemiaNew treatment programCombination of drugsComplete remissionComplete respondersCooperative trialsStage IIIChildhood leukemiaEffective drugsTreatment programTherapyUse of combinationsDiseasePilot studyFurther treatmentRemissionHodgkin's Disease Therapeutic Program
DeVita V. Hodgkin's Disease Therapeutic Program. JAMA 1972, 222: 1171-1171. PMID: 4678060, DOI: 10.1001/jama.1972.03210090051025.Peer-Reviewed Original ResearchConceptsCombination of drugsRemission durationHodgkin's diseaseCombinations of effective drugsProlongation of remission durationAdvanced Hodgkin's diseaseComplete remission rateAcute childhood leukemiaRemission rateProcarbazine hydrochlorideRate of inductionCooperative trialsEffective drugsChildhood leukemiaRemissionTherapyDrugPilot studyDiseaseHodgkinDurationMOPPProcarbazineMethotrexateLeukemiaCombination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy
Canellos G, Young R, DeVita V. Combination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy. Clinical Pharmacology & Therapeutics 1972, 13: 750-754. PMID: 5053816, DOI: 10.1002/cpt1972135part1750.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseCombination chemotherapyProlonged disease-free intervalExtensive radiation therapyAdvanced Hodgkin's diseaseDisease-free intervalEnd of radiotherapyOnset of chemotherapyCombination chemotherapy programsDegree of myelosuppressionExtensive radiotherapyIntensive radiotherapyCurative intentComplete remissionExtensive diseasePrevious radiotherapyRemission rateChemotherapy programRadiation therapyDrug toxicityPatientsRadiotherapyMonthly cyclesChemotherapyDisease
1971
Treatment of Advanced Hodgkin's Disease with [1,3 Bis (2-Chloroethyl)-L-Nitrosourea] BCNU
Young R, DeVita V, Serpick A, Canellos G. Treatment of Advanced Hodgkin's Disease with [1,3 Bis (2-Chloroethyl)-L-Nitrosourea] BCNU. New England Journal Of Medicine 1971, 285: 475-479. PMID: 5558887, DOI: 10.1056/nejm197108262850902.Peer-Reviewed Original Research